India  
 
NewsR.in

United States: Updates On Aflibercept BPCIA Litigation - Goodwin Procter LLP

Mondaq Monday, 19 February 2024
On Friday, January 20, 2024, Regeneron Pharmaceuticals, Inc. ("Regeneron") filed an ex parte application for a scheduling order setting the schedule for preliminary injunction proceedings or, in the alternative, an emergency status conference.
0
shares		ShareTweetSavePostSend
 

You Might Like


Related news from verified sources

United States: PTAB Institutes Celltrion And Biocon IPRs On Regeneron Aflibercept Dosing Patent - Goodwin Procter LLP

 Late last month, a Patent Trial and Appeal Board ("PTAB") panel instituted two petitions that were filed separately by Celltrion and Biocon for inter partes...
Mondaq